BURLINGTON…TriPath Imaging Inc. (Nasdaq:TPTH) says the Cervical Screenig Wales (the national Welsh cervical screeing organization) has signed a five year contract to use TriPath’s SurePath liquid-based Pap test exclusively.

Ray Swanson, senior vice president, commercial operations at TriPath said in a statement, “This represents a major success for TriPath Imaging as it is the first contract signed in the United Kingdom since the UK’s planned conversion to liquid-based Pap tests was approved by the National Institute for Clinical Excellencew last October.”

He said that since Wales was a pilot site for the alternative system, the UK, which will convert completely to the liquid-based system, represents attractive growth potential for the company.

“The Wales contract places us in a strong position to win additional regional contracts in the UK,” he said.